{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"97"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"36"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"98"}],"units":"Participants"}],"description":"TEAE was defined as an adverse event that had an onset date, or a worsening in severity on or after the first dose of study drug up to the end of the study. SAE was any untoward medical occurrence that at any dose: resulted in death; life threatening required inpatient hospitalization; resulted in persistent, significant disability; was congenital anomaly/birth defect or medically important due to other reasons than mentioned criteria. Number of participants with TEAEs and SAEs were reported.","groups":[{"description":"Participants were treated with E7777 6 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG000","title":"Lead-In Part: E7777 6 mcg/kg"},{"description":"Participants were treated with E7777 12 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG001","title":"Lead-In Part: E7777 12 mcg/kg"},{"description":"Participants were treated with E7777 15 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part.","id":"OG002","title":"Lead-In Part: E7777 15 mcg/kg"},{"description":"Participants were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG003","title":"Lead-In Part and Main Study Part: E7777 9 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Lead-In Part: SAS included all participants who received study drug. Main Study Part: SAS included all participants (both Main Study and Lead-In) who received study drug at 9 mcg/kg.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug up to 30 days after the last dose (Up to 3 years and 7 months)","title":"Lead-In Part and Main Study Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}